Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diroleuton - DS Biopharma

Drug Profile

Diroleuton - DS Biopharma

Alternative Names: 8,11,14-eicosatrienoic-acid; all-cis-8,11,14-eicosatrienoic-acid; Bishomo-gamma-linolenic acid; DGLA; DHLA; Dihomogammalinolenic-acid; DS 107E; DS-107G; DS-107J; DS107; Gamma-homolinolenic-acid; Homo-gamma-linolenic-acid; RO-12-1989

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dignity Sciences
  • Developer DS Biopharma
  • Class Anti-inflammatories; Antiacnes; Antipruritics; Eicosanoids; Omega-6 fatty acids; Skin disorder therapies; Small molecules
  • Mechanism of Action CD40 antigen inhibitors; Interleukin 10 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris; Atopic dermatitis; Pruritus
  • No development reported Radiation-induced skin damage; Wounds

Most Recent Events

  • 25 Jul 2019 Phase-II clinical trials in Atopic dermatitis in Latvia (PO) (EudraCT2019-000932-25) (NCT03817190)
  • 28 Jan 2019 DS Biopharma plans a phase II trial for Atopic dermatitis in June 2019 (NCT03817190) (EudraCT2019-000932-25)
  • 04 Jan 2019 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top